(353) Talazoparib Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: Safety Analyses From the Randomized, Placebo-Controlled, Phase 3 TALAPRO-2 Study
To provide a detailed overview of the safety profile of talazoparib plus enzalutamide in the all-comers population of the TALAPRO-2 trial with the aim of understanding how adverse events were managed.
Learning Objectives:
To provide a detailed overview of the safety profile of talazoparib plus enzalutamide in the all-comers population of the TALAPRO-2 trial with the aim of understanding how adverse events were managed.